CMC(SH:603122)2022-10-28 16:00Financial Performance - The company's operating revenue for Q3 2022 was ¥332,003,570.72, representing a year-on-year increase of 10.71%[5] - The net profit attributable to shareholders was ¥17,741,560.57, a decrease of 4.46% compared to the same period last year[7] - The basic earnings per share for the period was ¥0.04, down 33.33% due to an increase in the weighted average number of shares following the company's initial public offering[11] - Total operating revenue for the first three quarters of 2022 reached ¥956,356,057.38, an increase of 6.3% compared to ¥899,100,448.02 in the same period of 2021[20] - Net profit for the first three quarters of 2022 was ¥54,232,528.04, slightly higher than ¥53,755,012.91 in the same period of 2021, indicating a growth of 0.9%[21] - The comprehensive income total for the first three quarters of 2022 was ¥68,110,129.18, compared to ¥53,508,966.31 in the same period of 2021, an increase of 27.3%[21] Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,548,383,367.9, reflecting a 38.18% increase from the end of the previous year[6] - The total liabilities increased to ¥395,565,040.56 in Q3 2022 from ¥324,781,096.58 in Q3 2021, representing a growth of 21.8%[19] - The total equity attributable to shareholders reached ¥1,152,006,027.42, up from ¥795,832,606.71 in the previous year, marking an increase of 44.9%[19] Cash Flow - The cash flow from operating activities was not applicable for the current period, with a negative cash flow of ¥187,622,178.2 for the year-to-date[6] - In the first three quarters of 2022, the cash inflow from operating activities was approximately $795.74 million, a decrease of about 9.0% compared to $874.62 million in the same period of 2021[23] - The net cash flow from operating activities was negative at approximately -$187.62 million, worsening from -$63.12 million in the first three quarters of 2021[23] - The cash inflow from investment activities totaled approximately $3.37 million, an increase from $2.99 million in the same period of 2021[24] - The net cash flow from investment activities was negative at approximately -$52.77 million, compared to -$3.40 million in the first three quarters of 2021[24] - The cash inflow from financing activities was approximately $633.64 million, significantly higher than $254.92 million in the same period of 2021[24] - The net cash flow from financing activities was positive at approximately $287.60 million, a turnaround from -$86.27 million in the first three quarters of 2021[24] Shareholder Information - Total number of common shareholders at the end of the reporting period is 38,285[13] - The largest shareholder, 合富（香港）控股有限公司, holds 218,937,885 shares, representing 55.00% of total shares[13] - The company reported a total of 19,700,000 shares (4.95%) held by 招商局资本管理有限责任公司[13] Operational Challenges - The company experienced delays in customer payments due to recurring national pandemic issues, impacting cash flow and accounts receivable[11] - The company received government subsidies amounting to ¥1,100,000.00 during the year, which are closely related to its normal business operations[9] Inventory and Receivables - Accounts receivable increased to ¥812,752,306.14 from ¥545,653,297.06 year-over-year[16] - Inventory as of September 30, 2022, is ¥202,776,940.98, up from ¥178,858,307.89[17] Research and Development - Research and development expenses for the first three quarters of 2022 amounted to ¥2,269,736.91, indicating ongoing investment in innovation[20] Strategic Focus - The company plans to continue focusing on expanding its market presence and developing new technologies in the healthcare sector[1] - The company continues to focus on market expansion and new product development as part of its strategic initiatives[22]